Biohaven Pharma (BHVN) Misses Q1 EPS by 47c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Join SI Premium – FREE
Biohaven Pharma (NYSE: BHVN) reported Q1 EPS of ($2.17), $0.47 worse than the analyst estimate of ($1.70).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clover Health Investments (CLOV) Tops Q3 EPS by 1c ; Offers Guidance
- Amplitude, Inc. (AMPL) Tops Q3 EPS by 1c ; Offers Guidance
- Paycom Software (PAYC) Tops Q3 EPS by 56c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
